Tahoe Therapeutics

Tahoe Therapeutics is a San Francisco-based biotech startup, founded in 2021, that is pioneering a data-centric AI approach to drug discovery. The company's core asset is its generation of massive, proprietary single-cell datasets that capture how chemical and genetic perturbations affect cell biology, which are used to train predictive AI models. This platform aims to de-risk and accelerate the identification of novel therapeutics, particularly for hard-to-treat cancers, as evidenced by an active partnership to develop antibody-drug conjugates. Tahoe operates with an open-science ethos, having released a 100-million-cell dataset, and is backed by significant venture funding and collaborations with leading research institutes.

AI-powered virtual cell models trained on gigascale perturbative single-cell maps linking drug and genetic perturbations to cellular responses.

Tahoe competes in the crowded AI-driven drug discovery space with companies like Recursion, Exscientia, Insitro, and Relay Therapeutics. Its key differentiator is its proprietary focus on generating and leveraging massive-scale perturbative single-cell data to train its models, a more complex but potentially more informative data modality than the imaging or bulk omics data used by some competitors. Its open-data approach also distinguishes it from more closed platforms.